Efforts from the largest clinical trial in the field of corneal diseases and surgery is paying off.
The Cornea Preservation Time Study (CPTS), which began in 2012, involved more than 1,000 patients and 70 researchers from across the United States. Under the leadership of study chair Dr. Jonathan Lass, an Eversight Medical Director and the Charles I Thomas Professor of Ophthalmology at University Hospitals and Case Western Reserve University in Cleveland, the multicenter trial demonstrated that corneal tissues can be preserved for up to 11 days and still successfully grafted.
Researchers also assessed donor, recipient and operative factors that may contribute to endothelial cell loss. They noted that tissue from diabetic donors can lower graft success, increase cell loss at three years and result in higher rates of graft dislocation. Eversight CEO Kevin Ross was Chair of the Eye Bank Advisory Committee for the study.
“Eversight has a long history of sponsoring research projects that goes back to 1980,” Ross said. “It’s an incredible privilege for us to work with an innovative leader in the field of corneal transplantation like Dr. Lass. Together, we’re working to help advance eye banking practices.”
To learn more about the groundbreaking research, visit the Cornea Preservation Time Study’s website.
